BACKGROUND: Equitable access to health insurance coverage may improve outcomes of care for chronic health conditions and mitigate racial/ethnic health disparities. This study examines racial/ethnic disparities in the treatment and outcomes of care for TRICARE beneficiaries with congestive heart failure (CHF). METHODS: Using a retrospective cohort analysis, we examined demographic characteristics, sources of care, and comorbid conditions for 2183 beneficiaries of the Military Health System's TRICARE program (representing 115,584 beneficiaries after adjusting for survey weights) with CHF. Treatments included use of CHF-related medications, while the outcome of interest was any CHF-related potentially avoidable hospitalizations (PAHs). RESULTS: While African Americans were less likely than whites to have received beta blockers and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers following a CHF diagnosis (P<0.0001). Hispanics were, in some cases, equally likely as whites to receive pharmacological treatments for CHF. In multivariate models, there were no significant racial/ethnic differences in the odds of a PAH; age greater than 65 was the most significant predictor of a PAH. CONCLUSIONS: This study suggests that although there are some racial and ethnic disparities in the receipt of pharmacological therapy for CHF among TRICARE beneficiaries, these differences do not translate into disparities in the likelihood of a PAH. The findings support previous research suggesting that equal access to care may mitigate racial/ethnic health disparities.
BACKGROUND: Equitable access to health insurance coverage may improve outcomes of care for chronic health conditions and mitigate racial/ethnic health disparities. This study examines racial/ethnic disparities in the treatment and outcomes of care for TRICARE beneficiaries with congestive heart failure (CHF). METHODS: Using a retrospective cohort analysis, we examined demographic characteristics, sources of care, and comorbid conditions for 2183 beneficiaries of the Military Health System's TRICARE program (representing 115,584 beneficiaries after adjusting for survey weights) with CHF. Treatments included use of CHF-related medications, while the outcome of interest was any CHF-related potentially avoidable hospitalizations (PAHs). RESULTS: While African Americans were less likely than whites to have received beta blockers and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers following a CHF diagnosis (P<0.0001). Hispanics were, in some cases, equally likely as whites to receive pharmacological treatments for CHF. In multivariate models, there were no significant racial/ethnic differences in the odds of a PAH; age greater than 65 was the most significant predictor of a PAH. CONCLUSIONS: This study suggests that although there are some racial and ethnic disparities in the receipt of pharmacological therapy for CHF among TRICARE beneficiaries, these differences do not translate into disparities in the likelihood of a PAH. The findings support previous research suggesting that equal access to care may mitigate racial/ethnic health disparities.
Authors: James B Wetmore; Jonathan D Mahnken; Sally K Rigler; Edward F Ellerbeck; Purna Mukhopadhyay; Qingjiang Hou; Theresa I Shireman Journal: Am J Hypertens Date: 2012-12-28 Impact factor: 2.689
Authors: Andrew J Schoenfeld; Heeren Makanji; Wei Jiang; Tracey Koehlmoos; Christopher M Bono; Adil H Haider Journal: Clin Orthop Relat Res Date: 2017-12 Impact factor: 4.176
Authors: Mostafa El-Refai; Tara Hrobowski; Edward L Peterson; Karen Wells; John A Spertus; L Keoki Williams; David E Lanfear Journal: J Cardiovasc Med (Hagerstown) Date: 2015-09 Impact factor: 2.160
Authors: Shelby D Reed; Yanhong Li; Mark E Dunlap; William E Kraus; Gregory P Samsa; Kevin A Schulman; Michael R Zile; David J Whellan Journal: Am J Cardiol Date: 2012-07-03 Impact factor: 2.778
Authors: Rebecca E Scully; Andrew J Schoenfeld; Wei Jiang; Stuart Lipsitz; Muhammad Ali Chaudhary; Peter A Learn; Tracey Koehlmoos; Adil H Haider; Louis L Nguyen Journal: JAMA Surg Date: 2018-01-01 Impact factor: 14.766